

Lysophospholipid Receptors in the Nervous System*

Rachelle E. Toman^{1,2} and Sarah Spiegel^{2,3}

(Accepted March 29, 2002)

The lysophospholipid mediators, lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P), are responsible for cell signaling in diverse pathways including survival, proliferation, motility, and differentiation. Most of this signaling occurs through an eight-member family of G-protein coupled receptors once known as the endothelial differentiation gene (EDG) family. More recently, the EDG receptors have been divided into two subfamilies: the lysophosphatidic acid subfamily, which includes LPA₁, (EDG-2/VZG-1), LPA₂ (EDG-4), and LPA₃ (EDG-7), and the sphingosine-1-phosphate receptor subfamily, which includes S1P₁ (EDG-1), S1P₂ (EDG-5/ H218/AGR16), S1P₃ (EDG-3), S1P₄ (EDG-6), and S1P₅ (EDG-8/NRG-1). The ubiquitous expression of these receptors across species, coupled with their diverse cellular functions, has made lysophospholipid receptors an important focus of signal transduction research. Neuroscientists have recently begun to explore the role of lysophospholipid receptors in a number of cell types; this research has implicated these receptors in the survival, migration, and differentiation of cells in the mammalian nervous system.

KEY WORDS: G-protein-coupled receptor; lysophosphatidic acid; nervous system; sphingosine-1-phosphate.

INTRODUCTION

Lysophospholipids, including lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P), are metabolites of glycerophospholipids and sphingolipids, lipid components of cell membranes (Fig. 1). These lysophospholipids have both cell signaling properties and diverse functions, including the stimulation of mitogenesis, suppression of apoptosis, reorganization of the cytoskeleton, and regulation of cell movement (reviewed

in references 1–7). All of these roles may be important for the development of the nervous system (8,9). Their diverse actions, ubiquitous expression, and evolutionary conservation suggest that they play a critical role in a number of fundamental processes; they have been implicated in tumorigenesis, angiogenesis, immunity, and atherosclerosis, as well as, recently, in neuronal survival, differentiation, and neurotransmission.

LPA and S1P Metabolism


Lysophospholipids are produced by *de novo* synthesis and during metabolism of plasma membrane lipids, as well as at different subcellular sites (reviewed in references 1, 10, and 11). Surprisingly, although LPA is one of the simplest natural phospholipids and is considered to be a key intermediate in *de novo* lipid synthesis, little is known about its biosynthesis. Among the best-characterized cellular sources of bioactive

* Special issue dedicated to Dr. Guido Tettamanti.

¹ Interdisciplinary Program in Neuroscience and Department of Biochemistry and Molecular Biology, Georgetown University Medical Center, Washington, DC 20057.

² Department of Biochemistry, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia 23298.

³ Address reprint requests to: Sarah Spiegel, PhD, Department of Biochemistry and Molecular Biophysics, Medical College of Virginia Campus, Virginia Commonwealth University, 1101 E. Marshall St., P.O. Box 980614, Richmond, Virginia 23298-0614. Tel: (804) 828-9330; Fax: (804) 828-8999; E-mail: sspiegel@vcu.edu



Stimulate growth
 Suppress apoptosis
 Regulate motility
 Regulate calcium
 Role in cytoskeletal rearrangement

Fig. 1. Lysophospholipid structures.

LPA and S1P are blood platelets, which release these mediators following their activation (3). It has been reported that platelets release LPA when stimulated by thrombin or alpha-2-receptor agonists (12,13). Precisely how LPA is released into the extracellular environment remains unknown. It is believed that platelet-derived LPA is produced from newly generated phosphatidic acid by the action of phospholipase D followed by phospholipase A₂-mediated deacylation (3,14–16). However, recent results suggest that LPA is not released from activated platelets (17), suggesting that the source of extracellular LPA has not yet been discovered. Moreover, the extensive distribution of LPA receptors suggests that there may be more diverse sources. Other phospholipases including lysophospholipase D and phospholipase A₁ may also contribute to LPA production (14–16).

S1P is produced by the sphingosine kinase-dependent phosphorylation of sphingosine (reviewed in reference 10). Cellular levels of S1P are low and tightly controlled by the balance between its synthesis and degradation. Sphingosine kinase is activated by numerous external stimuli, including many growth and survival factors, leading to transient increases in S1P levels. This growing list includes PDGF (18), NGF (19), muscarinic acetylcholine agonists (20), cytokines such as TNF-α (21) and IL-1β (22), and the crosslinking of immunoglobulin receptors (23,24). S1P turnover is mediated either by dephosphorylation back to sphingosine catalyzed by specific S1P phosphatases (25,26) or irreversible cleavage by S1P lyase to hexadecenal and ethanolamine phosphate (27).




Fig. 2. Phylogenetic tree of lysophospholipid receptors.

Platelets have sphingosine kinase but lack S1P lyase activity and thus contain high levels of S1P. A recent study suggests that S1P, rather than LPA, is the major bioactive lysophospholipid that is released from platelets (17).

LPA and S1P Receptors

Once formed, LPA and S1P can act as both intracellular second messengers and extracellular mediators. Whereas specific targets for their intracellular actions have not yet been conclusively identified, their extracellular effects are mediated via a family of specific plasma membrane G-protein-coupled receptors, lysophospholipid receptors, previously known as EDG family receptors (1,7,10,11). As is characteristic of G-protein-coupled receptors, these lysophospholipid receptors have seven transmembrane spanning domains, are closely related to the cannabinoid receptors CB1A and CB2, and have been divided into two sub-

Table I. Properties of Lysophospholipid Receptors

Name	Coupled G-proteins	Downstream pathways
LPA ₁	Gα _i , Gα _o Gα _q , Gα ₁₁ , Gα ₁₄ Gα ₁₂ , Gα ₁₃	Adenylyl cyclase inhibition PLC activation PI3K activation Akt activation Rho activation DNA synthesis
LPA ₂	Gα _i , Gα _o Gα _q , Gα ₁₁ , Gα ₁₄ Gα ₁₂ , Gα ₁₃	Adenylyl cyclase inhibition MAPK activation PLC activation Arachadonic acid release Calcium mobilization
LPA ₃	Gα _i , Gα _o Gα _q , Gα ₁₁ , Gα ₁₄	Adenylyl cyclase stimulation or inhibition MAPK activation PLC activation Arachadonic acid release Calcium mobilization
S1P ₁	Gα _i , Gα _o	Adenylyl cyclase inhibition MAPK activation PLC activation Rho activation Calcium mobilization
S1P ₂	Gα _i , Gα _o Gα _q , Gα ₁₁ , Gα ₁₄ Gα ₁₂ , Gα ₁₃	Adenylyl cyclase stimulation MAPK activation PLC activation Rho activation Calcium mobilization
S1P ₃	Gα _i , Gα _o Gα _q , Gα ₁₁ , Gα ₁₄ Gα ₁₂ , Gα ₁₃	Adenylyl cyclase stimulation MAPK activation PLC activation Rho activation Calcium mobilization
S1P ₄	Gα _i , Gα _o	MAPK activation PLC activation
S1P ₅	Gα _i , Gα _o Gα ₁₂ , Gα ₁₃	Adenylyl cyclase inhibition MAPK inhibition PLC activation Calcium mobilization

families based on their ligand specificity. The LPA receptor subfamily includes LPA₁ (EDG-2/VZG-1), LPA₂ (EDG-4), and LPA₃ (EDG-7), and the S1P receptor subfamily includes S1P₁ (EDG-1), S1P₂ (EDG-5/H218/AGR16), S1P₃ (EDG-3), S1P₄ (EDG-6), and S1P₅ (EDG-8/NRG-1). This article is focused on the role of these lysophospholipid receptors in the nervous system where they are differentially expressed.

LPA₁

The first LPA receptor (LPA₁) was discovered in studies of gene expression during development of

mouse cerebral cortex. While performing experiments to identify novel GPCRs associated with neuronal production, Chun and colleagues (28) identified an orphan GPCR with an enriched expression pattern in the ventricular zone that they named VZG-1. Northern blot analysis first revealed that a 3.8-kb *vzg-1/lpa₁* transcript was expressed within the developing brain and later, in situ hybridization clearly demonstrated its expression in the cortical neuroblasts of the neuroproliferative ventricular zone (28,29). Membrane binding studies indicated that VZG-1 overexpression increased LPA specific binding. These analyses identified the *vzg-1* gene product as a receptor for LPA and suggested that LPA signaling mechanisms were important in cortical neurogenesis (28). Postnatally, LPA₁ is present in oligodendrocytes, the myelinating cells of the central nervous system; it is not expressed in astrocytes. Its expression is highest during the first several postnatal weeks and decreases to low levels in adulthood. Additionally, Schwann cells, the myelinating cells of the peripheral nervous system, maintain high levels of LPA₁ expression throughout life, suggesting a possible role for LPA₁ in myelination of the nervous system (30).

Although ligation of LPA₁ has been shown to stimulate cell proliferation, the extent and timing of this increase suggest that it may not be a biologically relevant role for LPA₁ in the nervous system (31). However, both morphological changes, including cell rounding and process retraction (28,32), and ionic changes, including increased chloride and nonselective cation conductances, in primary cortical neuroblasts and neuroblast cell lines have been attributed to activated LPA₁ (33). Such changes in conductance have previously been shown to influence DNA synthesis (34). Activated LPA₁ in primary Schwann cells enhances survival through a Gα_i-dependent process (31,35). In addition, LPA₁ can couple to other G proteins, including Gα₁₁, Gα₁₂, Gα₁₃, Gα₁₄, and Gα_q, in different cell types (36,37). LPA₁ also mediates activation of phosphatidylinositol 3-kinase, Akt and the Rho pathway (35), and inhibits cAMP production (28), important for regulation of cell survival and motility.

The importance of LPA₁ in the nervous system was emphasized by the phenotype of mice with a targeted deletion of LPA₁ that results in a high degree of neonatal lethality. Surviving newborns have impaired suckling ability, cerebral cortical neurons of reduced size, craniofacial dysmorphism, and increased apoptosis of the sciatic nerve (38). Taken together, these findings

suggest that LPA₁ plays a critical role in neuronal development and behavior, as well as in the maintenance and functioning of mature myelinating cells.

LPA₂

LPA₂ shares approximately 60% sequence similarity with LPA₁ (2,29). Intriguingly, the *lpa₂* gene is expressed in several variant forms in human cancer cells, one of which was used for the original characterization (36). However, Northern blot analysis using a wild-type LPA₂ probe revealed both 2.8- and 7-kb transcripts in embryonic and neonatal mouse brain, although neither transcript was detectable in adult brain tissue. By *in situ* hybridization, the 7-kb transcript was also shown to be temporally expressed, located in postmitotic neuronal regions and the ventricular zone of embryonic mice (39). The smaller LPA₂ transcript was also abundantly expressed in the adult testis, kidney, and lung (40).

LPA₂ couples to both G α_i and G α_q . Ligation of LPA₂ has been associated with activation of phospholipase C and extracellular signal regulated kinase (ERK), increases in intracellular calcium, release of arachadonic acid, production of inositol phosphate, and inhibition of cAMP formation (36,41). LPA₂ is also responsible for LPA-induced cell rounding of B103 rat neuroblastoma cells (41).

LPA₃

Like LPA₂, LPA₃ also shares approximately 60% sequence similarity with LPA₁. Its expression appears to be species specific, and it is abundantly expressed in human testis, prostate, heart, and frontal cortex (42,43) and in mouse lung, kidney, and testis (40). In contrast to LPA induced cell rounding in LPA₁- and LPA₂-expressing cells, overexpression of LPA₃ resulted in neurite extension in B103 cells and inhibited LPA-dependent cell rounding of primary mouse neuroblast cells that endogenously express LPA₁ and LPA₂ but not LPA₃ (41). LPA₃ mediates pertussis toxin (PTX)-insensitive intracellular calcium increases (42,43) and phospholipase C activation (41), indicating coupling to G proteins other than G α_i . Ligation of LPA₃ also activates ERK1/2, releases arachidonic acid, and inhibits cAMP accumulation (41). Contradictory findings have been reported regarding the coupling of LPA₃ to G α_i . Activation of LPA₃ stimulates adenylyl cyclase in insect cells (42), yet has no appar-

ent effect on cAMP levels in certain types of mammalian cells (43).

S1P₁

The LPA and S1P receptor subfamilies share approximately 35% sequence identity, yet the two families are notably distinguished by the presence of an intron in the coding region of the sixth transmembrane domain of the LPA subfamily (29). The first of the S1P receptors to be identified, EDG-1/S1P₁ was cloned as an immediate early gene induced during endothelial differentiation (44). While a 3.2-kb S1P₁ transcript is ubiquitously expressed throughout rat tissues, expression of a 4.9-kb S1P₁ transcript is restricted to the brain, the sympathetic neuronal-like PC12 cell line, and C6 glioma cells (45,46). S1P₁ expression is developmentally regulated; in the rat brain, S1P₁ mRNA is detected on embryonic day 15 and steadily increases, reaching its highest level in adulthood (45). Similar developmental expression patterns were reported for the mouse (47). Given that overexpression of S1P₁ in PC12 cells does not influence proliferation (45) and that S1P₁ is primarily expressed in the adult brain, it is more likely that S1P₁ plays a role in the maintenance of mature neurons rather than in the development of the nervous system. The recent finding that S1P₁ is expressed in the Zebrafish embryonic brain suggests that S1P signaling plays an evolutionarily conserved role in the central nervous system (48).

The role of S1P₁ signaling in the central nervous system is not yet well characterized and most of the available clues stem from studies in non-neuronal cells. For example, S1P₁ activation inhibits forskolin-stimulated intracellular cAMP accumulation in a PTX sensitive manner (49–51). In cells overexpressing S1P₁, sustained activation of ERK1/2, as well as S1P-stimulated phospholipase C, is also PTX sensitive. In CHO cells, but not in COS-7 or HEK 293 cells, S1P₁ has been associated with PTX-sensitive calcium mobilization (49–51). Since PTX ADP ribosylates and inactivates G $\alpha_{i/o}$ subunits, these findings indicate the tendency of S1P₁ to couple to these G proteins (49–54). Importantly, some S1P₁ actions are PTX insensitive and involve signaling pathways mediated by the small GTPases of the Rho family. These include morphological changes, as well as increased cadherin expression and formation of adherin junctions (53–55). These findings suggest S1P₁ may play a role in Rho-dependent pathways, such as neuritogenesis, in the developing nervous system.

Interestingly, disruption of *s1p1* causes an embryonic lethal deficit in vascular smooth muscle cell and pericyte migration to reinforce nascent blood vessels (56); similar results were obtained by disrupting the PDGF-BB or PDGFR- β genes (57,58). Recent studies have revealed that the binding of PDGF to its receptor activates and recruits sphingosine kinase to the cell's leading edge (59). In turn, ligation of S1P₁ results in activation and integration of downstream signals essential for cell motility, such as FAK, Src, and Rac (59,60). Moreover, PDGFR is also tethered to S1P₁, providing a platform for integrative signaling by these two types of receptors (61). These studies strongly implicate S1P₁ in the regulation of growth factor induced cell motility and cytoskeletal rearrangement, further suggesting that S1P₁ may play a role in neuronal migration and neuritogenesis.

S1P₂ and S1P₃

S1P₂ and S1P₃ are closely related and share 92% sequence identity. Thus, it is not surprising that their tissue distribution and the biological effects that they mediate are also very similar. These receptors are predominantly expressed in the lung, heart, kidney, liver, spleen, thymus, testis, and brain (62). S1P₂ and S1P₃ mediate both mitogenic and anti-apoptotic effects, enhancing cell survival of rat hepatoma cells. However, overexpression of these receptors in HEK 293 and PC12 cells has been associated with increased apoptosis, cell rounding, and neurite retraction (63). It has been suggested that S1P₂ and, to a lesser extent S1P₃, might be responsible for neurite retraction and soma rounding of neuroblastoma cells induced by S1P (63).

Both receptors mediate S1P-induced ERK1/2 activation through a G α_i -dependent pathway and rapidly induce c-Jun and c-Fos, suggesting induction of immediate early genes (64). In COS-7 cells and HEK 293 cells, activated S1P₂ and S1P₃ mediate PTX-sensitive calcium mobilization (65). Unlike S1P₁, S1P₂ and S1P₃ couple not only to G $\alpha_{i/o}$ but also to G α_q , G α_{12} , and G α_{13} (36,66,67) and activate several PTX-insensitive signaling pathways, including c-jun N-terminal kinase and p38, as well as stress fiber formation (63,68). Neurite retraction has been shown to involve G α_{12} , G α_{13} , and G α_q , as well as the Rho family of small G-proteins (69). Additionally, activation of Rho by these receptors may be mediated through G α_{12} and G α_{13} (R. E. Toman and N. H. Lee, unpublished data) facilitating the cytoskeletal changes noted after overexpression of S1P₂ and S1P₃. Regulation of intracellular

cAMP levels by S1P₂ and S1P₃ occurs in both PTX-sensitive and -insensitive manners, depending on cell type; this may also be a result of the diversity in G protein coupling (68,70).

While S1P₂ has long been implicated as an essential regulator of development, recent findings indicated an unanticipated role in neuronal excitability (71). S1P₂ is expressed in embryonic peripheral axons (72) and has been shown to mediate S1P-induced retraction of neurites in culture (63,73). However, no defects in peripheral axons were noted in newborn S1P₂ null mice (71). Still, these mice had spontaneous, sporadic seizures, had abnormal EEG readings, and displayed significant increases in spontaneous excitatory postsynaptic currents, as determined by whole-cell patch-clamp techniques (71). These observations suggest that S1P₂ may play an active role in neurotransmission. Considering that S1P₂ mediates decreased neurite length in PC12 cells, it has been suggested that deletion of S1P₂ may cause inappropriate establishment of neuronal connections (71), resulting in hyperexcitability and seizure induction.

S1P₅

The newest addition to the S1P receptor family, S1P₅, shares an overall sequence identity of 40–44% and a transmembrane region homology of 53–55% with its subfamily members. In contrast to other S1P receptors, expression of two similar sized mRNA transcripts of 2.2- and 2.8-kb have been detected, both of which are expressed almost exclusively in the brain. Both Northern analysis and EST expression profiling reveal that S1P₅ expression is particularly abundant in lower brain regions, including the midbrain, pons, medulla, and spinal cord (74). *In situ* hybridization has further revealed S1P₅ to be associated with white matter tracts in the central nervous system (43). Importantly, S1P₅ mRNA levels are downregulated in response to NGF, fibroblast growth factor, and dibutyryl cAMP in PC12 cells (74). This is in direct contrast to S1P₁ expression, which is unaffected by NGF treatment, and S1P₂, which is only transiently repressed (45,75). Strikingly, S1P₅ is expressed in E7 and E17 mice embryos, but not in E11 or E15 embryos (76). These findings suggest that S1P₅ may be particularly important in the process of developmental neuronal differentiation.

Differentiation of PC12 cells requires sustained activation of the ERK pathway (77) which might be dependent on protein kinase A (PKA) (78). Further-

more, S1P₅ downregulation is also PKA dependent (74), suggesting that S1P₅ may be a negative regulator of differentiation. Overexpression of S1P₅ in CHO cells results in a marked decrease of proliferation (79), while in PC12 cells, it induces PTX-insensitive neurite retraction (R. E. Toman, unpublished data), further supporting the notion that S1P₅ may be important in terminal differentiation.

S1P inhibits cAMP accumulation in a PTX-sensitive manner, in both CHO and Rh7777 cells overexpressing S1P₅, suggesting that S1P₅ couples to $G\alpha_{i/o}$ (43,79). Additional studies in *Xenopus laevis* oocytes demonstrated that S1P₅ coupled to $G\alpha_{o/i}$ and $G\alpha_{q/o}$ to induce calcium mobilization, but did not activate $G\alpha_{q/s}$ (43). In CHO cells overexpressing S1P₅, S1P repressed serum-induced phosphorylation of ERK1/2 in a PTX-insensitive yet orthovanadate- and okadaic acid-sensitive fashion. This pattern of regulation is reminiscent of the angiotensin-2 (AT₂) receptor as in cultured neurons, AT₂ inhibits serum activation of ERK1/2 (80), and in N1E-115 neuroblastoma cells, AT₂ receptors act through a PTX-insensitive and orthovanadate-sensitive pathway, possibly involving SHP-1 (81). It has been proposed that the antagonistic modulation of ERK activity by the AT₁ and AT₂ receptors acts as a molecular counterbalance system (80). It is tempting to speculate that differential activation of S1P receptors may function in a manner similar to that of the AT₁/AT₂ system. *In vitro* analysis revealed that S1P₅ also couples to $G\alpha_{12}$. Remarkably, binding of S1P to S1P₅ also resulted in specific phosphorylation of the p54 isoform of JNK (79). Thus, S1P₅ may be an important regulator of proliferation and differentiation in the mammalian nervous system.

CONCLUSION

Current research on LPA and S1P receptors suggests that they signal primarily through direct coupling to GPCRs. However, the reciprocal interaction of S1P₁ and PDGF, as well as the ability of S1P₅ to inhibit ERK activation by regulation of tyrosine phosphatases, suggests that lysophospholipid receptors may regulate GPCRs in unique ways. This would not be the first novel signaling pathway to play in a role in neuronal development. Recently, Flanagan and colleagues characterized the regulation of the GPCR, CXCR4, via the reverse signaling of Eph-B activation (82). In this system, the C terminus of bound ephrin-B binds PDZ-RGS3, which can inhibit heterotrimeric G-protein signaling through the guanine nucleotide activating

protein (GAP) activity of its RGS domain. It is tempting to speculate that PDZ-RGS3 might also regulate the function of lysophospholipid receptors.

It is known, however, that a major locus of expression for lysophospholipid receptors is the nervous system. Analysis has revealed S1P and LPA receptor expression in neuroblasts, neurons, and glial cells (28,30,43,74,83). The temporal expression of these receptors, together with their regulation of pathways crucial for survival, proliferation, migration, differentiation, and neurotransmission, suggests roles for LPA receptors and S1P receptors in both the developing and mature nervous system. Future analysis will certainly elucidate the regulatory roles of the lysophospholipid receptor signaling systems in these processes. Given that many biological functions are predominantly receptor driven, there is great potential of specific agonists and antagonists for these receptors for the treatment of developmental disorders as well as for neurodegenerative diseases.

REFERENCES

- Goetzl, E. J. and An, S. 1998. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. *FASEB J.* 12:1589–1598.
- Chun, J., Contos, J. J., and Munroe, D. 1999. A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs). *Cell Biochem. Biophys.* 30:213–242.
- Moolenaar, W. H. 1999. Bioactive lysophospholipids and their G protein-coupled receptors. *Exp. Cell Res.* 253:230–238.
- Goetzl, E. J., Lee, H., Dolezalova, H., Kalli, K. R., Conover, C. A., Hu, Y. L., Azuma, T., Stossel, T. P., Karliner, J. S., and Jaffe, R. B. 2000. Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. *Ann. N.Y. Acad. Sci.* 905:177–187.
- Pyne, S., Pyne, N. J. 2000. Sphingosine 1-phosphate signalling in mammalian cells. *Biochem. J.* 349:385–402.
- Spiegel, S. and Milstien, S. 2000. Functions of a new family of sphingosine-1-phosphate receptors. *Biochim. Biophys. Acta.* 1484:107–116.
- Hla, T., Lee, M. J., Ancellin, N., Paik, J. H., and Kluk, M. J. 2001. Lysophospholipids—receptor revelations. *Science.* 294:1875–1878.
- Postma, F. R., Jalink, K., and Hengeveld, T., Moolenaar, W. H. 1996. Sphingosine-1-phosphate rapidly induces rho-dependent neurite retraction: Action through a specific cell surface receptor. *EMBO J.* 15:2388–2392.
- Sato, K., Tomura, H., Igarashi, Y., Ui, M., and Okajima, F. 1997. Exogenous sphingosine 1-phosphate induces neurite retraction possibly through a cell surface receptor in PC12 cells. *Biochem. Biophys. Res. Commun.* 240:329–334.
- Spiegel, S. and Merrill, A. H., Jr. 1996. Sphingolipid metabolism and cell growth regulation. *FASEB J.* 10:1388–1397.
- Hannun, Y. A., Luberto, C., and Argraves, K. M. 2001. Enzymes of sphingolipid metabolism: From modular to integrative signaling. *Biochemistry* 40:4893–4903.
- Eichholtz, T., Jalink, K., Fahrenfort, I., and Moolenaar, W. H. 1993. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. *Biochem. J.* 291:677–680.

13. Pages, C., Simon, M. F., Valet, P., and Saulnier-Blache, J. S. 2001. Lysophosphatidic acid synthesis and release. *Prostaglandins Other Lipid Mediat.* 64:1–10.
14. Fourcade, O., Simon, M. F., Viode, C., Rugani, N., Leballe, F., Ragab, A., Fournie, B., Sarda, L., and Chap, H. 1995. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. *Cell* 80:919–927.
15. Gaits, F., Fourcade, O., Le Balle, F., Gueguen, G., Gaige, B., Gassama-Diagne, A., Fauvel, J., Salles, J. P., Mauco, G., Simon, M. F., and Chap, H. 1997. Lysophosphatidic acid as a phospholipid mediator: Pathways of synthesis. *FEBS Lett.* 410:54–58.
16. Tokumura, A., Okuno, M., Fukuzawa, K., Houchi, H., Tsuchiya, K., and Oka, M. 1998. Positive and negative controls by protein kinases of sodium-dependent Ca^{2+} efflux from cultured bovine adrenal chromaffin cells stimulated by lysophosphatidic acid. *Biochim. Biophys. Acta.* 1389:67–75.
17. Yatomi, Y., Ohmori, T., Rile, G., Kazama, F., Okamoto, H., Sano, T., Satoh, K., Kume, S., Tigyi, G., Igarashi, Y., and Ozaki, Y. 2000. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. *Blood* 96:3431–3438.
18. Olivera, A. and Spiegel, S. 1993. Sphingosine-1-phosphate as a second messenger in cell proliferation induced by PDGF and FCS mitogens. *Nature* 365:557–560.
19. Edsall, L. C., Pirianov, G. G., and Spiegel, S. 1997. Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. *J. Neurosci.* 17: 6952–6960.
20. Meyer zu Heringdorf, D., Lass, H., Alemany, R., Laser, K. T., Neumann, E., Zhang, C., Schmidt, M., Rauen, U., Jakobs, K. H., and van Koppen, C. J. 1998. Sphingosine kinase-mediated Ca^{2+} signalling by G-protein-coupled receptors. *EMBO J.* 17: 2830–2837.
21. Xia, P., Gamble, J. R., Rye, K. A., Wang, L., Hii, C. S. T., Cockerill, P., Khew-Goodall, Y., Bert, A. G., Barter, P. J., and Vadas, M. A. 1998. Tumor necrosis factor- α induces adhesion molecule expression through the sphingosine kinase pathway. *Proc. Natl. Acad. Sci. U.S.A.* 95:14196–14201.
22. Nikolova-Karakashian, M., Morgan, E. T., Alexander, C., Liotta, D. C., and Merrill, A. H., Jr. 1997. Bimodal regulation of ceramidase by interleukin-1 β . Implications for the regulation of cytochrome p450 2C11. *J. Biol. Chem.* 272:18718–18724.
23. Choi, O., H., Kim, J.-H., and Kinet, J.-P. 1996. Calcium mobilization via sphingosine kinase in signalling by the Fc ϵ RI antigen receptor. *Nature* 380:634–636.
24. Melendez, A., Floto, R. A., Gillooly, D. J., Harnett, M. M., and Allen, J. M. 1998. Fc γ RI coupling to phospholipase D initiates sphingosine kinase-mediated calcium mobilization and vesicular trafficking. *J. Biol. Chem.* 273:9393–9402.
25. Mandala, S. M., Thornton, R., Galve-Roperh, I., Poulton, S., Peterson, C., Olivera, A., Bergstrom, J., Kurtz, M. B., and Spiegel, S. 2000. Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine-1-phosphate and induces cell death. *Proc. Natl. Acad. Sci. U.S.A.* 97: 7859–7864.
26. Le Stunff, H., Peterson, C., Thornton, R., Milstien, S., Mandala, S. M., and Spiegel, S. 2002. Characterization of Murine Sphingosine-1-phosphate Phosphohydrolase. *J. Biol. Chem.* 277: 8920–8927.
27. Van Veldhoven, P. P., Gijsbers, S., Mannaerts, G. P., Vermeesch, J. R., and Brys, V. 2000. Human sphingosine-1-phosphate lyase: cDNA cloning, functional expression studies and mapping to chromosome 10q22(1). *Biochim. Biophys. Acta.* 487:128–134.
28. Hecht, J. H., Weiner, J. A., Post, S. R., and Chun, J. 1996. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. *J. Cell Biol.* 135:1071–1083.
29. Contos, J. J. and Chun, J. 1998. Complete cDNA sequence, genomic structure, and chromosomal localization of the LPA receptor gene, 1pA1/vzg-1/Gpcr26. *Genomics* 51:364–378.
30. Weiner, J. A., Hecht, J. H., and Chun, J. 1998. Lysophosphatidic acid receptor gene vzg-1/1pA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. *J. Comp. Neurol.* 398:587–598.
31. Fukushima, N., Kimura, Y., and Chun, J. 1998. A single receptor encoded by vzg-1/1pA1/edg-2 couples to G proteins and mediates multiple cellular responses to lysophosphatidic acid. *Proc. Natl. Acad. Sci. U.S.A.* 95:6151–6156.
32. Fukushima, N., Weiner, J. A., and Chun, J. 2000. Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. *Dev. Biol.* 228:6–18.
33. Dubin, A. E., Bahnson, T., Weiner, J. A., Fukushima, N., and Chun, J. 1999. Lysophosphatidic acid stimulates neurotransmitter-like conductance changes that precede GABA and L-glutamate in early, presumptive cortical neuroblasts. *J. Neurosci.* 19:1371–1381.
34. LoTurco, J. J., Owens, D. F., Health, M. J., Davis, M. B., and Kriegstein, A. R. 1995. GABA and glutamate depolarize cortical progenitor cells and inhibit DNA synthesis. *Neuron* 15: 1287–1298.
35. Weiner, J. A. and Chun, J. 1999. Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. *Proc. Natl. Acad. Sci. U.S.A.* 96:5233–5238.
36. An, S., Bleu, T., Hallmark, O. G., and Goetzl, E. J. 1998. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. *J. Biol. Chem.* 273:7906–7910.
37. Yoshida, A. and Ueda, H. 1999. Activation of Gi1 by lysophosphatidic acid receptor without ligand in the baculovirus expression system. *Biochem. Biophys. Res. Commun.* 259:78–84.
38. Contos, J. J., Fukushima, N., Weiner, J. A., Kaushal, D., and Chun, J. 2000. Requirement for the 1pA1 lysophosphatidic acid receptor gene in normal suckling behavior. *Proc. Natl. Acad. Sci. U.S.A.* 97:13384–13389.
39. Fukushima, N. and Chun, J. 2001. The LPA receptors. *Prostaglandins Other Lipid Mediat.* 64:21–32.
40. Contos, J. J., Ishii, I., and Chun, J. 2000. Lysophosphatidic acid receptors. *Mol. Pharmacol.* 58:1188–1196.
41. Ishii, I., Contos, J. J., Fukushima, N., and Chun, J. 2000. Functional comparisons of the lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system. *Mol. Pharmacol.* 58:895–902.
42. Bandoh, K., Aoki, J., Hosono, H., Kobayashi, S., Kobayashi, T., Murakami-Murofushi, K., Tsujimoto, M., Arai, H., and Inoue, K. 1999. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. *J. Biol. Chem.* 274:27776–27785.
43. Im, D. S., Heise, C. E., Ancellin, N., O'Dowd, B. F., Shei, G. J., Heavens, R. P., Rigby, M. R., Hla, T., Mandala, S., McAllister, G., George, S. R., and Lynch, K. R. 2000. Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. *J. Biol. Chem.* 275:14281–14286.
44. Hla, T. and Maciag, T. 1990. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein coupled receptors. *J. Biol. Chem.* 265:9308–9313.
45. Lado, D. C., Browe, C. S., Gaskin, A. A., Borden, J. M., and MacLennan, A. J. 1994. Cloning of the rat *edg-1* immediate-early gene: Expression pattern suggests diverse functions. *Gene* 149:331–336.
46. Sato, K., Ui, M., and Okajima, F. 2000. Differential roles of Edg-1 and Edg-5, sphingosine 1-phosphate receptors, in the signaling pathways in C6 glioma cells. *Brain Res. Mol. Brain Res.* 85:151–160.
47. Liu, C. H. and Hla, T. 1997. The mouse gene for the inducible G-protein-coupled receptor *edg-1*. *Genomics* 43:15–24.

48. Im, D. S., Ungar, A. R., Lynch, K. R. 2000. Characterization of a zebrafish (*Danio rerio*) sphingosine 1-phosphate receptor expressed in the embryonic brain. *Biochem. Biophys. Res. Commun.* 279:139–143.
49. Okamoto, H., Takuwa, N., Gonda, K., Okazaki, H., Chang, K., Yatomi, Y., Shigematsu, H., and Takuwa, Y. 1998. EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca^{2+} mobilization, ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. *J. Biol. Chem.* 273:27104–27110.
50. Van Brocklyn, J. R., Lee, M. J., Menzeleev, R., Olivera, A., Edsall, L., Cuvillier, O., Thomas, D. M., Coopman, P. J. P., Thangada, S., Hla, T., and Spiegel, S. 1998. Dual actions of sphingosine-1-phosphate: Extracellular through the G_i-coupled orphan receptor edg-1 and intracellular to regulate proliferation and survival. *J. Cell Biol.* 142:229–240.
51. Zondag, G. C. M., Postma, F. R., Etten, I. V., Verlaan, I., and Moolenaar, W. H. 1998. Sphingosine 1-phosphate signalling through the G-protein-coupled receptor Edg-1. *Biochem. J.* 330:605–609.
52. Wu, J., Spiegel, S., and Sturgill, T. W. 1995. Sphingosine 1-phosphate rapidly activates the mitogen-activated protein kinase pathway by a G protein-dependent mechanism. *J. Biol. Chem.* 270:11484–11488.
53. Lee, M.-J., Evans, M., and Hla, T. 1996. The inducible G protein-coupled receptor *edg-1* signals via the G_i/mitogen-activated protein kinase pathway. *J. Biol. Chem.* 271:11272–11282.
54. Lee, M. J., Van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S., and Hla, T. 1998. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. *Science* 279:1552–1555.
55. Stam, J. C., Michiels, F., Kammen, R. A., Moolenaar, W. H., and Collard, J. G. 1998. Invasion of T-lymphoma cells: Cooperation between Rho family GTPases and lysophospholipid receptor signaling. *EMBO J.* 17:4066–4074.
56. Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C. X., Hobson, J. P., Rosenfeldt, H. M., Nava, V. E., Chae, S. S., Lee, M. J., Liu, C. H., Hla, T., Spiegel, S., and Proia, R. L. 2000. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. *J. Clin. Invest.* 106:951–961.
57. Lindahl, P., Johansson, B. R., Leveen, P., and Betsholtz, C. 1997. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. *Science* 277:242–245.
58. Hellstrom, M., Kaln, M., Lindahl, P., Abramsson, A., and Betsholtz, C. 1999. Role of PDGF- β and PDGFR- β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. *Development* 126:3047–3055.
59. Rosenfeldt, H. M., Hobson, J. P., Maceyka, M., Olivera, A., Nava, V. E., Milstien, S., and Spiegel, S. 2001. EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration. *FASEB J.* 15:2649–2659.
60. Hobson, J. P., Rosenfeldt, H. M., Barak, L. S., Olivera, A., Poulton, S., Caron, M. G., Milstien, S., and Spiegel, S. 2001. Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. *Science* 291:1800–1803.
61. Alderton, F., Rakhit, S., Choi, K. K., Palmer, T., Sambhi, B., Pyne, S., and Pyne, N. J. 2001. Tethering of the platelet-derived growth factor beta receptor to G-protein coupled receptors: A novel platform for integrative signaling by these receptor classes in mammalian cells. *J. Biol. Chem.* 276:12452–12460.
62. Zhang, G., Contos, J. J., Weiner, J. A., Fukushima, N., and Chun, J. 1999. Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate. *Gene* 227:89–99.
63. Van Brocklyn, J. R., Tu, Z., Edsall, L. C., Schmidt, R. R., and Spiegel, S. 1999. Sphingosine 1-phosphate-induced cell rounding and neurite retraction are mediated by the G protein-coupled receptor H218. *J. Biol. Chem.* 274:4626–4632.
64. An, S., Zheng, Y., and Bleu, T. 2000. Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5. *J. Biol. Chem.* 275:288–296.
65. An, S., Bleu, T., Huang, W., Hallmark, O. G., Coughling, S. R., and Goetzl, E. J. 1997. Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. *FEBS Lett.* 417:279–282.
66. An, S., Bleu, T., and Zheng, Y. 1999. Transduction of intracellular calcium signals through G protein-mediated activation of phospholipase C by recombinant sphingosine 1-phosphate receptors. *Mol. Pharmacol.* 55:787–794.
67. Ancellin, N. and Hla, T. 1999. Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5. *J. Biol. Chem.* 274:18997–19002.
68. Gonda, K., Okamoto, H., Takuwa, N., Yatomi, Y., Okazaki, H., Sakurai, T., Kimura, S., Sillard, R., Harii, K., and Takuwa, Y. 1999. The novel sphingosine 1-phosphate receptor AGR16 is coupled via pertussis toxin-sensitive and -insensitive G-proteins to multiple signalling pathways. *Biochem. J.* 337:67–75.
69. Katoh, H., Aoki, J., Yamaguchi, Y., Kitano, Y., Ichikawa, A., and Negishi, M. 1998. Constitutively active G α 12, G α 13, and G α 14 induce Rho-dependent neurite retraction through different signaling pathways. *J. Biol. Chem.* 273:28700–28707.
70. Kon, J., Sato, K., Watanabe, T., Tomura, H., Kuwabara, A., Kimura, T., Tamama, K., Ishizuka, T., Murata, N., Kanda, T., Kobayashi, I., Ohta, H., Ui, M., and Okajima, F. 1999. Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cDNA-transfected Chinese hamster ovary cells. *J. Biol. Chem.* 274:23940–23947.
71. MacLennan, A. J., Carney, P. R., Zhu, W. J., Chaves, A. H., Garcia, J., Grimes, J. R., Anderson, K. J., Roper, S. N., and Lee, N. 2001. An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. *Eur. J. Neurosci.* 14:203–209.
72. MacLennan, A. J., Marks, L., Gaskin, A. A., and Lee, N. 1997. Embryonic expression pattern of H218, a G-protein coupled receptor homolog, suggests roles in early mammalian nervous system development. *Neuroscience* 79:217–224.
73. MacLennan, A. J., Devlin, B. K., Marks, L., Gaskin, A. A., Neitzel, K. L., and Lee, N. 2000. Antisense studies in PC12 cells suggest a role for H218, a sphingosine 1-phosphate receptor, in growth-factor-induced cell-cell interaction and neurite outgrowth. *Dev. Neurosci.* 22:283–295.
74. Glickman, M., Malek, R. L., Kwitek-Black, A. E., Jacob, H. J., and Lee, N. H. 1999. Molecular cloning, tissue-specific expression, and chromosomal localization of a novel nerve growth factor-regulated G-protein-coupled receptor, nrg-1. *Mol. Cell. Neurosci.* 14:141–152.
75. MacLennan, A. J., Browe, C. S., Gaskin, A. A., Lado, D. C., and Shaw, G. 1994. Cloning and characterization of a putative G-protein coupled receptor potentially involved in development. *Mol. Cell Neurosci.* 5:201–209.
76. Im, D. S., Clemens, J., Macdonald, T. L., and Lynch, K. R. 2001. Characterization of the human and mouse sphingosine 1-phosphate receptor, SIP₍₅₎ (Edg-8): Structure-activity relationship of sphingosine-1-phosphate receptors. *Biochemistry* 40:14053–14060.
77. Heasley, L. E. and Johnson, G. L. 1992. The beta-PDGF receptor induces neuronal differentiation of PC12 cells. *Mol. Biol. Cell* 3:545–553.

78. Yao, H., York, R. D., Misra-Press, A., Carr, D. W., and Stork, P. J. 1998. The cyclic adenosine monophosphate-dependent protein kinase (PKA) is required for the sustained activation of mitogen-activated kinases and gene expression by nerve growth factor. *J. Biol. Chem.* 273:8240–8247.
79. Malek, R. L., Toman, R. E., Edsall, L. C., Wong, S., Chiu, J., Letterle, C. A., Van Brocklyn, J. R., Milstien, S., Spiegel, S., and Lee, N. H. 2001. Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosine-1-phosphate receptors. *J. Biol. Chem.* 276:5692–5699.
80. Huang, X. C., Summers, C., and Richards, E. M. 1996. Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal cells via type 2 receptors in a pertussis toxin sensitive fashion. *Adv. Exp. Med. Biol.* 396:209–215.
81. Bedecs, K., Elbaz, N., Sutren, M., Masson, M., Susini, C., Strosberg, A. D., and Nahmias, C. 1997. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. *Biochem. J.* 325:449–454.
82. Lu, Q., Sun, E. E., Klein, R. S., and Flanagan, J. G. 2001. Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemoattraction. *Cell.* 105:69–79.
83. Allard, J., Barron, S., Diaz, J., Lubetzki, C., Zalc, B., Schwartz, J. C., and Sokoloff, P. 1998. A rat G protein-coupled receptor selectively expressed in myelin-forming cells. *Eur. J. Neurosci.* 10:1045–1053.